청심연자탕으로 호전된 올리브교소뇌위축증 환자 치험 1례 = A Case Report of a Patient with Olivopontocerebellar Atrophy Improved with Chengsimyeonja-tang

다국어 초록 (Multilingual Abstract)

Objectives This study aimed to report significant improvement of dizziness, gait disturbance and dysarthria after treatment with Sasang constitutional medicine treatment on a Taeeumin patient with olivopontocerebellar atrophy. Methods A 53-year-old female diagnosed olivopontocerebellar atrophy about one year ago suffered from dizziness, gait disturbance and dysarthria. The patient was identified as Taeeumin Joyeol pattern and treated with Cheongsimyeonja-tang and Taegeuk acupuncture. The patient's main symptoms were observed using Global Assessment Scale (GAS) during the treatment period. In addition, the Unified Multiple System Atrophy Rating Scale (UMSARS) was used to assess the overall function of patient. Results We observed a significant improvement in symptoms of dizziness, gait disturbance and dysarthria using GAS, and UMSARS score decreased in Part I and II. Conclusions This case showed that Sasang constitutional medicine treatment can be effective treatment for Taeeumin patient with olivopontocerebellar atrophy. We consider that consistent treatment can contribute to improve the patient's quality of life.

참고문헌 (Reference)

1 정민호, "복시를 호소하는 다계통위축증 환자 치험 1례" 대한한방내과학회 38 (38): 246-251, 2017

2 우성진, "보행장애를 주소로 하는 소뇌형 다계통 위축증 환자의한방 치료 1례" 대한한방내과학회 37 (37): 806-814, 2016

3 김민지, "다계통 위축증의 치료에 대한 임상연구 동향 - CNKI검색을 중심으로" 대한한방내과학회 41 (41): 612-623, 2020

4 이미숙, "調胃升淸湯으로 호전된 올리브교소뇌위축증 환자 1례" 사상체질의학회 25 (25): 243-253, 2013

5 고가연, "荊防地黃湯으로 호전된 少陽人 소뇌위축증 환자의 眩暈 치험 1례" 사상체질의학회 25 (25): 233-242, 2013

6 신승원, "太陰人 病證 진단 알고리즘 개발 연구" 사상체질의학회 24 (24): 28-39, 2012

7 Ozawa T, "The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy : clinicopathological correlations" 127 : 2657-2671, 2004

8 Schrag A, "Survival in multiple system atrophy" 23 : 294-296, 2008

9 Gilman S, "Second consensus statement on the diagnosis of multiple system atrophy" 71 : 670-676, 2008

10 Bensimon G, "Riluzole treatment, survival and diag-nostic criteria in Parkinson plus disorders: the NNIPPS study" 132 : 156-171, 2009

11 Wenning GK, "Recent developments in multiple system atrophy" 256 : 1791-1808, 2009

12 Geser F, "Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG)" 21 : 179-186, 2006

13 Cho HS, "Principle and Prescription of Sansang Constitutional Medicine" Jipmoondang 435-447, 2003

14 May S, "Potential outcome measures and trial design issues for multiple system atrophy" 22 : 2371-2377, 2007

15 Savoiardo M, "Olivopontocerebellar atrophy: MR diagnosis and relationship to multisystem atrophy" 174 : 693-696, 1990

16 D J burns, "Multiple system atrophy: cellular and molecular pathology" 54 : 419-426, 2001

17 Yabe I, "MSA-C is the predominant clinical phenotype of MSA in Japan : analysis of 142 patients with probable MSA" 249 : 115-121, 2006

18 Yoshio Y., "A sakura Internal Medicine" Wooriuihakseojeok 322-325, 2020

19 Baik YS, "A clinical case study on multiple system atrophy-C" (spr) : 119-126, 2008

20 Im JW, "A case report of mutiple system atrophy patient treated by Korean medicine" 206-210, 2013